healio.com 11 Jun, 2021 13:30 am

Hydrogel capsule for weight loss may reduce risk for liver fibrosis

Hydrogel capsule for weight loss may reduce risk for liver fibrosis
An oral hydrogel capsule for treatment of obesity may reduce liver fibrosis risk, according to an exploratory analysis of the GLOW study presented at the American Association of Clinical Endocrinology annual meeting.“We know that patients with excess weight are at increased risk for developing nonalcoholic fatty liver disease, or NAFLD,” Christopher Still, DO, FACP, medical director

Since we collected all of the clinical values that are used to calculate the NAFLD fibrosis score as part of GLOW, it was a natural question to ask whether [hydrogel therapy] could impact participants’ NAFLD fibrosis score.Examining NAFLD risk For the exploratory analysis, Still and colleagues examined the impact of hydrogel therapy on liver health among 317 GLOW participants, as measured by the NAFLD fibrosis score, which predicts the presence of significant fibrosis using common clinical and laboratory values.NAFLD fibrosis score was categorized as higher (combining intermediate and high; score –1.7% in the placebo group had a NAFLD fibrosis score in the higher probability for fibrosis category (P = .

” At the end of treatment, more participants in the hydrogel group were in the lower probability risk category for NAFLD fibrosis score (P = .In the overall cohort, there was a statistically significant reduction in the absolute mean change in NAFLD fibrosis score for the hydrogel group (mean, –0.

Read full story at healio.com